Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CG0070||Oncolytic adenovirus encoding GM-CSF||CG0070 is a recombinant adenovirus that selectively infects, replicates and produces GM-CSF in tumor cells, which leads to tumor lysis and cytotoxic T cell-mediated tumor cell death (PMID: 16397056, PMID: 28755959).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||urinary bladder cancer||not applicable||CG0070||Phase II||Actionable||In a Phase II trial, treatment with CG0070 resulted in a complete response rate of 47% (21/45) in patients with BGC-unresponsive high grade non-muscle invasive bladder cancer (PMID: 28755959; NCT02365818).||28755959|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02365818||Phase II||CG0070||Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure||Completed||USA||0|
|NCT01438112||Phase II||Valrubicin Mitomycin C CG0070 Interferon gamma Gemcitabine||Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer (BOND)||Terminated||USA||0|